---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027716"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:24:22.735965+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro reports record FY2024 revenue $31.4M, 31% growth; guides FY2025 $36-41M

## Summary
- FY 2024 revenue $31.4M (+31% YoY); Q4 revenue $7.8M (+14% YoY).
- Gross margin improved to 61% from 57%; operating expenses rose 8% to $38.9M.
- Repaid $10M convertible note; cash $20.1M; operational cash burn down 35% to $9.0M.
- 2025 revenue guidance $36-41M, implying 15-31% growth.
- Biologics/drug delivery revenue up 76% to $18.6M; added 25 new centers in 2024.

## SEC filing metadata
- accession: 0000950170-25-027716
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000095017025027716/0000950170-25-027716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000095017025027716/clpt-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027716
- JSON: https://secwatch.observer/filing/0000950170-25-027716.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.